Author:
Schumacher Martin,Schmoor Claudia
Publisher
Springer Berlin Heidelberg
Reference20 articles.
1. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freyetes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, McCarthy PL Jr., Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO, Horowitz MM High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. Journal of Clinical Oncology 1997; 15:1870-1879.
2. Antman KH. A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer (review). European Journal of Cancer 2001; 37:173-179.
3. Bezwoda WR. Randomised, controlled trial of high dose chemotherapy (HD-CNV/p) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Journal of Clinical Oncology 1999; 17, No. 11s, 21d.
4. Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in woman with breast cancer and 10 or more positive axilliary lymph nodes. Journal of Clinical Oncology 1996; 14: 66-69.
5. Farquhar C, Marjoribanks J, Basser R, Lethaby A. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. The Cochrane Data Base of Systematic Reviews 2008, Volume 2.